<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01918683</url>
  </required_header>
  <id_info>
    <org_study_id>UPCC 16213</org_study_id>
    <nct_id>NCT01918683</nct_id>
  </id_info>
  <brief_title>TACE With or Without SBRT as Bridging Therapy for Pre-transplant HCC Patients</brief_title>
  <official_title>A Pilot Trial of Transarterial Chemoembolization With or Without Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma Patients Awaiting Liver Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abramson Cancer Center of the University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Loyola University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Abramson Cancer Center of the University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is designed to be the initial prospective pilot investigation of the effectiveness
      of combined SBRT and TACE as bridging therapy for HCC patients awaiting liver transplanation.
      No prospective clinical trials regarding the combination of TACE and SBRT in pre-transplant
      population have been performed. We propose the trial be conducted as a pilot clinical trial
      with the goal of enrolling 40 patients into each arm
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to determine whether the combination of stereotatic body
      radiotherapy (SBRT) tand transarterial chemoembolization (TACE) is an effective &quot;bridging
      therapy&quot; for patients hepatocellular carcinoma (HCC) of the liver awaiting transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">July 2017</completion_date>
  <primary_completion_date type="Anticipated">July 2017</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>10 days</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Hepatocellular Carcinoma Within Milan Criteria for Liver Tranplantation</condition>
  <arm_group>
    <arm_group_label>A -Tace alone</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>A - TACE alone (control group, current practice and treatment)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B - Tace combined with SBRT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>B- TACE combined with SBRT (experimental group).</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>TACE transarterial chemoembolization</intervention_name>
    <arm_group_label>A -Tace alone</arm_group_label>
    <arm_group_label>B - Tace combined with SBRT</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotatic body radiotherapy (SBRT)</intervention_name>
    <arm_group_label>B - Tace combined with SBRT</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient capable of giving informed consent

          -  Patient diagnosed with hepatocellular carcinoma and listed or recommended to be listed
             for orthotopic liver transplantation at the participating institution

          -  Age &gt; 18 years old

          -  Meets clinical criteria for eligibility for TACE to the target lesion per
             Interventional Radiology

          -  Childs' Class A or B7

          -  Eastern Clinical Oncology Group performance status 0 or 1

        Exclusion Criteria:

          -  Prior radiotherapy to the upper abdomen or radioembolization of the liver

          -  Prior TACE to the target lesion, RFA, or liver transplant

          -  Active GI bleed within 2 weeks of study enrollment

          -  Active GI ulcer disease within 4 weeks of study enrollment

          -  Ascites refractory to medical therapy

          -  Contraindication to receiving radiotherapy or TACE

          -  Complete obstruction of portal venous flow to the segment of liver that includes the
             target lesion

          -  Contraindication to both contrast enhanced MRI and contrast enhanced CT (i.e. unable
             to undergo follow-up imaging or SBRT treatment planning)

          -  Women who are pregnant

          -  Participation in another concurrent treatment protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edgar Ben-Josef, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abramson Cancer Center of the University of Pennsylvania</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tarita Thomas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loyola University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edgar Ben-Josef, MD</last_name>
    <phone>877-204-9213</phone>
    <email>PennCancerTrials@emergingmed.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Loyola University Medical Center</name>
      <address>
        <city>Maywood</city>
        <state>Illinois</state>
        <zip>60153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beth Chiappetta, RN</last_name>
      <phone>708-216-2568</phone>
      <email>BCHIAPPETTA@lumc.edu</email>
    </contact>
    <investigator>
      <last_name>Tarita Thomas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abramson Cancer Center of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgar Ben-Josef, MD</last_name>
      <phone>877-204-9213</phone>
      <email>PennCancerTrials@emergingmed.com</email>
    </contact>
    <investigator>
      <last_name>Edgar Ben-Josef, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 7, 2013</study_first_submitted>
  <study_first_submitted_qc>August 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2013</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

